Nike Heads Into Earnings With Short Sellers Retreating

NKE enters its November 16 earnings report in an unusual position: short sellers have been quietly reducing exposure while the stock recovers ground, yet the analyst community remains sharply divided on whether the turnaround story is real or premature.

The stock closed at $38.48 on November 3, up 2.4% on the week and 13.6% over the past month. That recovery has come against a backdrop of meaningful short covering. Short interest now runs at 8.3% of the free float, around 99 million shares, and has fallen 2.4% week-on-week. The month-long trend is worth watching more closely, though: shorts actually added over the full 30-day window, with the position up roughly 1.2% from a month ago. The bigger move happened in early October, when short interest spiked toward 102 million shares before retreating. The borrow market tells a consistent story: cost to borrow is just 0.50%, classified as low, and availability has actually loosened materially. At 635% availability, there are more than six shares in the lending pool for every one already borrowed, up from a tighter 346% at the start of October when short pressure was heaviest. The options market is calm. The put/call ratio sits at 0.69, barely above its 20-day average of 0.68, and the z-score of 0.91 shows no unusual hedging. Taken together, positioning looks more cautious than extreme.

The Street debate is where the real tension sits. Bulls point to margin recovery in progress: North America gross margin up approximately 110 basis points, EMEA up around 150, and the Pace restructuring program targeting roughly $2.5 billion in cumulative savings through FY31. Barclays lifted its target to $45 from $37 on October 22, maintaining Overweight. Guggenheim and BTIG both hold Buy ratings with $50 targets. Against that, Wolfe Research initiated with an Underperform and a $28 target the same day, citing weak innovation and ongoing franchise resets in Jordan Brand, Air Force 1 and Dunk. Morgan Stanley stays Underweight at $27. UBS is Neutral at $34. The consensus price target runs at $36.44, which sits below the current price of $38.48. That's an unusual configuration for a stock the bulls argue is cheap: even the average target implies the market has already priced in more than the Street's central case. The factor score picture adds nuance. EPS momentum ranks in the 9th percentile over 30 days and 5th over 90 days, and the 12-month forward EPS year-on-year trend ranks in the 1st percentile. The stock's dividend score, by contrast, ranks 99th. Quality is holding up; it is momentum that remains broken.

One alt data point is worth flagging, though not as a lead indicator. Wikipedia page views for Nike are running at a z-score of nearly 2.9 relative to the company's own 90-day history, as of October 23, suggesting retail attention has jumped. ORTEX has not found this dataset to lead Nike's reported figures, so it is colour rather than signal. What is verifiable is that Nike's buyback spend in Q2 2026 came in at zero, the smallest on record going back to 2010. With capital allocation under scrutiny and new CFO Dave Denton explicitly focused on shareholder value, the absence of buybacks in that quarter is a data point the bulls will need to reconcile.

The earnings history reinforces the caution. The last reported print, on October 1, saw the stock fall 4.3% the following day and close the subsequent week down 1.9%. The prior pattern offers no comfort to those expecting a smooth recovery. Among peers, the week was broadly positive: COLM jumped 14.5%, AS rose 8.2%, and DECK gained 4.4%. Nike's 2.4% advance looked modest by comparison, consistent with a stock where sentiment is improving but conviction remains low.

With the next print 43 days away on December 17, the question heading into the November 16 report is whether the margin recovery story can hold up under Greater China scrutiny, where footwear revenue fell 26% in the most recent quarter, and whether the Pace cost saves are showing up fast enough to satisfy a market that has already watched the stock fall roughly 40% year-to-date.